COMPANY
Prime Medicine
Since the raise (Aug 1, 2025): 9 of 9 open jobs were first seen after it.
Hiring
| Title | Location (from posting) | Employer posted | First seen |
|---|---|---|---|
| Senior Manager, Regulatory Operations | Cambridge, MA | Oct 7, 2026 | Oct 9, 2026 |
| Associate Scientist/Engineer II Technology, Development and Operations - Chemistry | Cambridge, MA | Oct 7, 2026 | Oct 9, 2026 |
| Research Associate, Automation & Assays | Cambridge, MA | Oct 7, 2026 | Oct 9, 2026 |
| VP, Regulatory Affairs | Cambridge, MA | Oct 2, 2026 | Oct 9, 2026 |
| Laboratory Operations Specialist | Cambridge, MA | Sep 18, 2026 | Oct 9, 2026 |
Timeline
- Board tracked Radar started tracking this company’s job board (9 open jobs at last check). source ↗
- Trial start Phase 1/Phase 2: A Study of the Safety and Efficacy of Prime Editing (PM577) in Participants With Wilson Disease (WD) source ↗
- Trial start —: Prescreening Study to Identify Potential Wilson Disease Participants for Gene-Editing Clinical Trial source ↗
- Raise Follow-on offering: $144.2M (total, as published), announced Aug 1, 2025. Source: company release on GlobeNewswire. source ↗
- Raise Private placement: $24M (up to, as announced), announced Jul 16, 2025. Source: company release on GlobeNewswire. source ↗
- Trial start Phase 1/Phase 2: A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD ) source ↗
Upcoming milestones
- 2027-12 (ESTIMATED) · · Prescreening Study to Identify Potential Wilson Disease Participants for Gene-Editing Clinical Trial · NCT07226622
- 2028-11 (ESTIMATED) · Phase 1/Phase 2 · A Study of the Safety and Efficacy of Prime Editing (PM577) in Participants With Wilson Disease (WD) · NCT07748403
- 2030-01 (ESTIMATED) · Phase 1/Phase 2 · A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD ) · NCT06559176
Open jobs 9
| Title | Location (from posting, not HQ) | Employer posted | First seen | Level |
|---|---|---|---|---|
| Senior Manager, Regulatory Operations | Cambridge, MA | Oct 7, 2026 | Oct 9, 2026 | Senior |
| Associate Scientist/Engineer II Technology, Development and Operations - Chemistry | Cambridge, MA | Oct 7, 2026 | Oct 9, 2026 | Mid |
| Research Associate, Automation & Assays | Cambridge, MA | Oct 7, 2026 | Oct 9, 2026 | Mid |
| VP, Regulatory Affairs | Cambridge, MA | Oct 2, 2026 | Oct 9, 2026 | Executive |
| Laboratory Operations Specialist | Cambridge, MA | Sep 18, 2026 | Oct 9, 2026 | Mid |
| Medical Director, Clinical Development | Cambridge, MA | Sep 10, 2026 | Oct 9, 2026 | Senior |
| Senior Quality Engineering Specialist | Cambridge, MA | Sep 7, 2026 | Oct 9, 2026 | Senior |
| Senior Scientist / Senior Engineer, LNP Process Development | Cambridge, MA | Jul 17, 2026 | Oct 9, 2026 | Mid |
| Senior Director, Biometrics | Cambridge, MA | Jul 8, 2026 | Oct 9, 2026 | Senior |
Funding
Clinical trials (lead sponsor) 3
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT07748403 | A Study of the Safety and Efficacy of Prime Editing (PM577) in Participants With Wilson Disease (WD) | Phase 1/Phase 2 | Recruiting | 2026-09 | 2028-11 (estimated) |
| NCT07226622 | Prescreening Study to Identify Potential Wilson Disease Participants for Gene-Editing Clinical Trial | Not listed | Active, not recruiting | Dec 29, 2025 | 2027-12 (estimated) |
| NCT06559176 | A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD ) | Phase 1/Phase 2 | Enrolling by invitation | Oct 17, 2024 | 2030-01 (estimated) |
Connect
See your connections at Prime Medicine on LinkedIn (search by name, results not checked)